

# ALLEN S. HO, MD

8635 W. Third St. Suite 590W  
Los Angeles, CA 90048

Office: (310) 423-1220  
Email: [allen.ho@cshs.org](mailto:allen.ho@cshs.org)

## ACADEMIC APPOINTMENTS

Los Angeles, CA **Cedars-Sinai Medical Center: Department of Surgery / Oschin Comprehensive Cancer Institute**  
2014 – Present Professor of Surgery. Director, Head & Neck Cancer Program. Co-Director, Thyroid Cancer Program.

## EDUCATION & TRAINING

New York, NY **Memorial Sloan Kettering Cancer Center: Department of Surgery, Head & Neck Service**  
2011 – 2014 Senior Fellow and Instructor in Surgery.

Palo Alto, CA **Stanford University School of Medicine: Department of Otolaryngology - Head & Neck Surgery**  
2006 – 2011 General Surgery internship (2006 – 2007). Chief residency (2010 – 2011).

Los Angeles, CA **University of California, Los Angeles School of Medicine**  
2001 – 2006 MD conferred in June 2006. Howard Hughes Medical Institute Research Scholar.

Cambridge, MA **Harvard University**  
1996 – 2000 BA in Neurobiology conferred in June 2000. Graduated *magna cum laude* with Highest Honors in Field.

## AWARDS

2018	Top Doctors/Super Doctors/Best Doctors	2004	Academy of Achievement Honoree
2013	Cedars-Sinai Patient Satisfaction Award	2002	Short Term Training Program Research Grant
2013	NYHNS Proffered Paper Session: 2 <sup>nd</sup> Place	2001	CA Med. Assoc. Leadership Acad. Scholarship
2012	AHNS Poster Session: Honorable Mention	2000	Harvard Univ. Honors Thesis: <i>magna cum laude</i>
2011 – 12	AAO-HNS Resident Leadership Grant (x2)	1999	Harvard College Research Program Grant
2009 – 11	Triological Society Resident Travel Award (x2)	1999	Harvard Undergraduate Council Grant
2004 – 05	HHMI Research Travel Grant (x3)	1999	Harvard President Public Service Fund Grant
2004	Nathan R. Lazar Medical Scholarship	1996 – 00	National Merit Scholarship
2004	Chinese American Physician Soc. Scholarship	1996 – 00	Harvard College Scholarship
2004	Chinese American Medical Soc. Scholarship	1996 – 97	John Harvard Scholarship

## PUBLICATIONS

### 2021 - PRESENT

1. Tabatabai R, Maya M, **Ho AS**, Zumsteg ZA, Gutierrez R, Sepehri S, Stokol C, Mita M, Mita A. Fluorouracil-induced leukoencephalopathy [submitted].
2. Mallen-St. Clair J, **Ho AS**, Epstein JB, Sheyn D. Cell based treatment for osteoradionecrosis of the jaw – an emerging treatment paradigm [submitted].
3. Nguyen AT, Luu M, Nguyen VP, Lu DJ, Shiao SL, Kamrava M, Atkins KM, Mita AC, Scher KS, Spratt DE, Faries MB, Daskivich TJ, Lin D, Chen MM, Mallen-St. Clair J, Sandler HM, **Ho AS**, Zumsteg ZS. The universality of parallel increasing quantitative nodal burden and mortality across solid cancers [submitted].
4. Horowitz G, Ritter A, **Ho AS**, Shpitzer T, Bachar G, Muhanna N, Mizrachi A. Surgeons' approach toward active surveillance in patient with low-risk papillary thyroid carcinoma: A survey of the American Head and Neck Society [submitted].
5. Mott NM, Miller J, Zumsteg ZS, **Ho AS**, Mallen-St. Clair J, Mierzwa MM, Casper KA, Prince ME, Dossett LA, Chen MM. Financial distress and hardship in head and neck cancer patients [submitted].
6. Lu DJ, Luu M, Gay C, Anderson EM, Scher K, Mita A, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. Association of pathologic nodal metastasis count with oncologic outcomes in head and neck cancer: a secondary analysis of RTOG 9501, RTOG 0234, and EORTC 22931 [submitted].
7. Anderson EM, Luu M, Lu DJ, Gay C, Scher K, Mita A, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. Predicting pathologic lymph node positivity in cN0 pharynx and larynx cancers in the modern imaging era [submitted].
8. **Ho AS**, Zalt C, Kim S, Melany ML, Chen IE, Vasquez J, Mallen-St. Clair J, Chen MM, Fan X, van Deen WK, Haile RW, Daskivich TJ, Zumsteg ZZ, Braunstein GD, Sacks WL. Expanded parameters in active surveillance for low-risk papillary thyroid cancer: a prospective clinical trial [submitted].

9. Sinclair C, Buczek E, Cottlil E, Angeles P, Barczynski M, **Ho AS**, Makarin V, Musholt T, Scharpf J, Schneider R, Stack B, Tellez M, Tolley N, Woodson G, Wu C, Randolph G. Clarifying optimal outcome measures in intermittent and continuous laryngeal neuromonitoring. *Head & Neck* [accepted].
10. **Ho AS**, Robinson A, Shon W, Laury A, Raedschelders K, Venkatraman V, Holewinski R, Zhang Y, Shiao SL, Chen MM, Mallen-St. Clair J, Lin D, Zumsteg ZS, Van Eyk JE. Comparative proteomic analysis of HPV(+) oropharyngeal squamous cell carcinoma recurrence. *Journal of Proteome Research* [accepted].
11. **Ho AS**, Luu M, Shafqat I, Mallen-St. Clair J, Chen MM, Chen Y, Jain M, Ali N, Patio C, Filarski CF, Lin D, Bankston H, Braunstein GD, Sacks WL, Zumsteg ZS. Predictive impact of nodal burden on distant metastasis across papillary thyroid cancer variants. *Thyroid*. 2021 Sep 2. PMID 34470466.
12. Nguyen AT, Luu M, Nguyen VP, Hamid O, Faries MB, Gharavi NM, Lu DJ, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. Development and validation of a modified pathologic nodal classification system for cutaneous melanoma. *JAMA Surgery*. 2021 Sep 1:e214298. PMID 34468697.
13. Li L, Yang Q, Jiang Y, Yang W, Jiang Y, Li X, Hazawa M, Zhou B, Huang G, Xu X, Gery S, Zhang Y, Ding L, **Ho AS**, Zumsteg ZS, Wang M, Freedland SJ, Xu L, Li E, Koeffler HP, Lin D. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. *Nature Communications*. 2021 Jul 16;12(1):4362. PMID 34272396.
14. **Ho AS**, Luu M, Kim S, Tighiouart M, Mita AC, Scher KS, Mallen-St. Clair J, Walgama ES, Lin D, Nguyen AT, Zumsteg ZS. Nodal staging convergence for HPV(-) and HPV(+) oropharyngeal cancer. *Cancer*. 2021 Feb 17. PMID 33595897.
15. Maul X, Dincer BC, Wu AW, Thamboo AV, Higgins TS, Scangas GA, Oliveira K, **Ho AS**, Mallen-St. Clair J, Walgama E. A clinical decision analysis for use of antibiotic prophylaxis for non-absorbable nasal packing. *Otolaryngology-Head and Neck Surgery*. 2021 Feb 16:194599820988740. PMID 33588621.
16. Barrios I, Shafqat, Alam U, Ali N, Patio C, Filarski C, Luu M, Zumsteg ZS, Adashek K, Chen Y, Jain M, Mallen-St. Clair J, Braunstein GD, Sacks WL, **Ho AS**. Incidental parathyroidectomy in thyroidectomy and central neck dissection. *Surgery*. 2021 Jan 11:S0039-6060(20)30808-4. PMID 33446359.
17. Filarski CF, Levine B, Buttan A, Gonzalez N, **Ho AS**. Enlarged hemorrhagic lingual thyroid managed with transoral robotic surgery. *Endocrine*. 2021 Jan 9. PMID 33420947.

#### 2016 – 2020

18. Anderson EM, Luu M, Balzer B, Scher K, Mita A, Lu DJ, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. Variations in the association of grade with survival across the head and neck cancer landscape. *Head and Neck*. 2020 Dec 10. doi: 10.1002/hed.26566. PMID 33300641.
19. Walgama E, Randolph GW, Lewis C, Tolley N, Sacks WL, Chen Y, **Ho AS**. Fiberoptic laryngoscopy is cost-effective prior to total thyroidectomy for low-risk thyroid cancer patients. *Head & Neck*. 2020 Sep;42(9):2593-2601. PMID: 32510729.
20. Patel H, Saadat N, **Ho AS**, Mallen-St. Clair J. Virtual surgical planning for bisphosphonate-related osteonecrosis of the jaw - a valuable application in advanced cases. *Cureus*. 2020 Aug 12;12(8):e9696. PMID 32923286.
21. Shafqat I, **Ho AS**, Manzoor D, Balzer B, Wu AW. Management of FDG avid benign sinonasal Schneiderian papilloma during the COVID-19 crisis: a case report and review of the literature. *Annals of Otolaryngology, Rhinology, and Laryngology*. 2020 Aug 27:3489420952478. Online ahead of print. PMID 32847383.
22. **Ho AS**, Luu M, Barrios L, Bose S, Fan X, Balzer BL, Walgama ES, Mallen-St. Clair J, Alam U, Shafqat I, Lin D, Chen Y, Maghami EG, Braunstein GD, Sacks WL, Zumsteg ZS. Prognostic impact of histologic grade for papillary thyroid carcinoma. *Annals of Surgical Oncology*. 2020 Aug 17. PMID 32808161.
23. Nguyen AT, Luu M, Mallen-St. Clair J, Mita AC, Scher KS, Lu DJ, Shiao SL, **Ho AS**, Zumsteg ZS. Comparison of survival after transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma. *JAMA Oncology*. 2020 Aug 20. PMID 32816023.
24. Yoshida EJ, Luu M, Freeman M, Essner R, Gharavi N, Shiao SL, Hamid O, **Ho AS**, Zumsteg ZS. The association between facility volume and overall survival in patients with merkel cell carcinoma. *Journal of Surgical Oncology*. 2020 Aug;122(2):254-262. PMID 32297324.
25. Lu DJ, Luu M, Nguyen AT, Shiao SL, Scher K, Mita A, Anderson E, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. The role of concomitant chemoradiotherapy in AJCC 7th Edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era. *Oral Oncology*. 2020 Jul 7. PMID: 32650257.

26. Tam M, Luu M, Barker C, Gharavi N, Hamid O, Shiao SL, Nguyen AT, Lu DJ, **Ho AS**, Zumsteg ZS. Improved survival in women versus men with Merkel cell carcinoma. *Journal of the American Academy of Dermatology*. J Surg Oncol. 2020 Apr 15. PMID 32423829.
27. Fong A, Jain M, Sacks WL, **Ho AS**, Chen Y. Crowdfunding campaigns and thyroid surgery: Who, what, where, and how much? *Journal of Surgical Research*. 2020 Apr 19;253:63-68. PMID 32320898.
28. Barrios L, Walgama E, Chen Y, Sacks WL, **Ho AS**. Emerging social media trends in thyroid and parathyroid surgery. *Annals of Thyroid*. 2020; 5:5. doi: 10.21037/aot.2020.03.02.
29. **Ho AS**, Luu M, Barrios L, Chen I, Melany M, Ali N, Patio C, Chen Y, Bose S, Fan X, Mallen-St. Clair J, Braunstein GD, Sacks WL, Zumsteg ZS. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. *JAMA Oncology*. 2020 May 1;6(5):706-713. PMID 32134428.
30. Nguyen AT, Luu M, Lu DJ, Hamid O, Mallen-St. Clair J, Gharavi N, **Ho AS**, Zumsteg ZS. Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. *Journal of the American Academy of Dermatology*. 2020 Jan 16;S0190-9622(20)30062-1. PMID: 31954753.
31. Yoshida EJ, Luu M, Mallen-St. Clair J, Mita A, Scher K, Lu DP, Nguyen A, Shiao SL, **Ho AS**, Zumsteg ZS. Stage I HPV-positive oropharyngeal cancer: should all patients receive similar treatments? *Cancer*. 2020 Jan 1;126(1):58-66. PMID: 31536144.
32. Walgama E, Sacks WL, **Ho AS**. Papillary thyroid microcarcinoma: optimal management versus overtreatment. *Current Opinion in Oncology*. 2020 Jan;32(1):1-6. PMID 31633497.
33. Sittig MP, Luu M, Yoshida EJ, Scher K, Mita A, Shiao SL, Lu DP, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. Impact of insurance on survival in patients age <65 with head and neck cancer treated with radiotherapy. *Clinical Otolaryngology*. 2020 Jan;45(1):63-72. PMID 31661188.
34. Lu, DJ, Luu M, Nguyen AT, Scher K, Mallen-St. Clair J, Mita A, Shiao SL, **Ho AS**, Zumsteg ZS. Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papilloma virus (HPV) prevalence. *Oral Oncology*. 2019 Nov 5; 99:104472. PMID 31704556.
35. **Ho AS**, Ochoa A, Tepe J, Makarov V, Dalin MG, Zehir A, Jayakumaran G, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Valero Mayor C, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha PK, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LGT. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. *Journal of Clinical Investigation*. 2019 Oct 1;129(10):4276-4289. PMID: 31483290.
36. **Ho AS**, Luu M, Zalt C, Morris LGT, Chen I, Melany M, Ali N, Patio C, Chen Y, Mallen-St. Clair J, Braunstein GD, Sacks WL, Zumsteg ZS. Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance. *Thyroid*. 2019 Oct; 29(10):1409-1417. PMID 31407637.
37. **Ho AS**, Daskivich, TJ, Sacks WL, Zumsteg ZS. Parallels between low-risk prostate and thyroid cancer. *JAMA Oncology*. 2019 Jul 1;5(7):975-983. PMID 30543358.
38. Aro K, **Ho AS**, Luu M, Kim S, Tighiouart M, Yoshida EJ, Mallen-St. Clair J, Shiao SL, Leivo I, Zumsteg ZS. Survival impact of adjuvant therapy in salivary gland cancers following resection and neck dissection. *Otolaryngology-Head and Neck Surgery*. 2019 Jun;160(6):1048-1057. PMID 30721113.
39. Yagi S, Arcega R, **Ho AS**, Balzer B. Unusual presentation of primary syphilis as retropharyngeal chancre. *OTO Open*. 2019 Apr 23;3(2):2473974X19841867. PMID 31428723.
40. Guneri P, Maghami E, Boyacioglu H, **Ho AS**, Epstein JB. Meta-analysis of oral potentially malignant disorders: surgical management versus observational surveillance of dysplastic lesions. *Otorhinolaryngology-Head and Neck Surgery*. 2019 Mar; 4:1-6.
41. Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher K, Lu DP, Shiao SL, Mallen-St. Clair J, **Ho AS**. Quantitative lymph node burden as a "very-high risk" factor identifying head and neck cancer patients benefiting from post-operative chemoradiation. *Annals of Oncology*. 2019 Jan 1;30(1):76-84. PMID 30395159.
42. Marcadis AR, Marti JL, **Ho AS**, Valderrabano P, Tepe J, Swartzwelder CE, Byrd S, Untch BR, Shaha AR, Xu B, Lin O, Ghossein RA, Wong RJ, Morris LGT. Interinstitutional variation in predictive value of the Thyroseq v2 genomic classifier for cytologically indeterminate thyroid nodules. *Surgery*. 2019 Jan;165(1):17-24. PMID 30360906.
43. **Ho AS**, Chen I, Melany M, Sacks WL. Evolving management trends in active surveillance for papillary thyroid microcarcinoma. *Current Opinion in Endocrinology, Diabetes, and Obesity*. 2018 Oct;25(5):353-359. PMID 30153222.

44. Lu DJ, Luu M, Mita A, Scher K, Shiao SL, Yoshida EJ, Sitting M, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. HPV-associated oropharyngeal cancer among patients aged 70 and older: dramatically increased prevalence and clinical implications. *European Journal of Cancer*. 2018 Sep 27;103:195-204. PMID 30268920.
45. Aro K, **Ho AS**, Luu M, Kim S, Tighiouart M, Mallen-St. Clair J, Yoshida EJ, Shiao SL, Leivo I, Zumsteg ZS. Development of a novel salivary gland cancer nodal staging system. *Cancer*. 2018 Aug 1;124(15):3171-3180. PMID 29742277.
46. **Ho AS**, Kim S, Tighiouart M, Mita A, Scher K, Laury A, Prasad R, Ali N, Patio C, Mallen-St. Clair J, Zumsteg ZS. Quantitative survival impact of composite treatment delays in head and neck cancer. *Cancer*. 2018 Aug 1;124(15):3154-3162. PMID 29742280.
47. **Ho AS**, Kim S, Tighiouart M, Gudino C, Mita A, Scher K, Laury A, Prasad R, Shiao SL, Ali N, Patio C, Mallen-St. Clair J, Van Eyk J, Zumsteg ZS. Association of quantitative metastatic lymph node burden with survival in hypopharyngeal and laryngeal cancer. *JAMA Oncology*. 2018 Jul 1;4(7):985-989. PMID 29192305.
48. Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, **Ho AS**, Zumsteg ZS. Postoperative chemoradiation in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension, and the influence of nodal classification. *Head & Neck*. 2018 Jun;40(6):1228-1236. PMID 29417700.
49. Marti JL, Morris LG, **Ho AS**. Selective use of radioactive iodine (RAI) in thyroid cancer: no longer “one size fits all.” *European Journal of Surgical Oncology*. 2018 Mar;44(3):348-356. PMID 28545679.
50. Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Lee NY, **Ho AS**, Zumsteg ZS. Facility volume and survival in nasopharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*. 2018 Feb;100(2):408-417. PMID 29100787.
51. Chen A, Ali N, Boasberg P, **Ho AS**. Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab. *Journal of Clinical Medicine*. 2018 Jan 10;7(1). pii: E10. PMID 29320468.
52. Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita A, Scher K, Sherman E, Lee NY, **Ho AS**. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: an analysis of the National Cancer Data Base. *Cancer*. 2017 Dec 1;123(23):4583-4593. PMID 28817183.
53. **Ho AS**, Kim S, Tighiouart M, Gudino C, Mita A, Scher K, Laury A, Prasad R, Shiao SL, Van Eyk J, Zumsteg ZS. Metastatic lymph node burden and survival in oral cavity cancer. *Journal of Clinical Oncology*. 2017 Nov 1;35(31):3601-3609. PMID 28880746.
54. Bin X, Drill E, **Ho AS**, Ho, AL, Dunn L, Pireto-Granada CN, Chan TA, Ganly I, Ghossein R, Katabi N. Predictors of outcomes in adenoid cystic carcinoma of salivary glands: clinicopathologic study with correlation with MYB fusion and protein expression *American Journal of Surgical Pathology*. 2017 Oct;41(10):1422-1432. PMID 28719465.
55. David J, **Ho AS**, Luu M, Yoshida EJ, Kim S, Tighiouart M, Mita A, Scher K, Shiao SL, Zumsteg ZS. Treatment at high volume facilities and academic centers are independently associated with improved survival in locally advanced head and neck cancer. *Cancer*. 2017 Oct 15;123(20):3933-3942. PMID 28640546.
56. Schmidt MQ, David JM, Yoshida EJ, Scher K, Mita A, Shiao SL, **Ho AS**, Zumsteg ZS. Predictors of survival in head and neck mucosal melanomas: A National Cancer Data Base Analysis. *Oral Oncology*. 2017 Oct; 73:36-42. PMID 28939074.
57. Wong FK, Zumsteg ZS, Langevin CJ, Ali N, Maclary S, Balzer BL, **Ho AS**. Mucinous carcinoma with neuroendocrine differentiation of salivary gland origin. *Head and Neck Pathology*. 2017 Jun;11(2):249-255. PMID 27534564.
58. Zumsteg ZS, Kim S, Yoshida E, David J, Tighiouart M, Mita A, Sherman E, Lee NY, **Ho AS**. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. *Cancer*. 2017 May 1;123(9):1555-1565. PMID 28001302.
59. Epstein JB, Song P, **Ho AS**, Larian B, Asher A, Bensadoun R. Photobiomodulation therapy: management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patients. *Supportive Care in Cancer*. 2017 Apr;25(4):1031-1034. PMID 27988865.
60. Zumsteg ZS, Lok B, **Ho AS**, Riaz N, Shiao SL, McBride S, Tsai J, Baxi S, Sherman E, Lee NJ. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 and older with oropharyngeal carcinoma in the intensity modulated radiotherapy era. *Cancer*. 2017 Apr 15; 123(8): 1345-1353. PMID 27984656.
61. Samim F, Epstein JB, Zumsteg ZS, **Ho AS**, Barash A. Oral and dental health in head and neck cancer survivors. *Cancers of the Head and Neck*. 2016;1:14.

62. **Ho AS**, Meyer A, Riaz N, Rahmati R, Kraus DK, McCarthy C, Wong RJ, Shah JP, Lee NY. Impact of flap reconstruction on radiotoxicity after salvage surgery and reirradiation for recurrent HN cancer. *Annals of Surgical Oncology*. 2016 Dec; 850-857. PMID 27506662.
63. Zumsteg ZS, Cook-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, Jeon C, Goodman MT, **Ho AS**. Increasing incidence of oropharyngeal cancer among elderly patients in the United States. *JAMA Oncology*. 2016 Dec 1;2(12):1617-1623. PMID 27415639.
64. Sacks WL, Bose S, Zumsteg ZS, Wong R, Shiao SL, Braunstein GD, **Ho AS**. Impact of Afirma GEC on cytopathology diagnosis and rate of thyroidectomy. *Cancer Cytopathology*. 2016 Oct; 124(10):722-728. PMID 27347838.

#### 2011 - 2015

65. Marti JL, Avadhani V, Donatelli LA, Niyogi S, Wang B, Wong RJ, Shaha AR, Ghossein RA, Lin O, Morris LGT, **Ho AS**. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. *Annals of Surgical Oncology*. 2015 Nov;22(12):3996-4001. PMID 25862581.
66. **Ho AS**, Davies L, Nixon IJ, Palmer FL, Wang LY, Patel SG, Ganly I, Wong RJ, Tuttle RM, Morris LGT. Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. *Cancer*. 2015 Jun 1; 121(11):1793-9. PMID 25712809.
67. **Ho AS**, Wang L, Palmer FL, Yu C, Tosef A, Patel S, Kattan MW, Tuttle RM, Ganly I. Postoperative nomogram for predicting cancer-specific mortality in medullary thyroid cancer. *Annals of Surgical Oncology*. 2015 Aug; 22(8):2700-6. PMID 25366585.
68. **Ho AS**, Sarti ES, Wang H, Jain KS, Shaha AR, Shah JP, Tuttle RM, Ghossein R, Wong RJ, Lin O, Morris LG. Malignancy rate in thyroid nodules classified as atypia of undetermined significance. *Thyroid*. 2014 May; 24(5):832-9. PMID 24341462.
69. **Ho AS**, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Eng S, Turcan S, Ramaswami D, Shah JP, Singh B, Dolgalev I, Heguy A, Viale A, Drobnjak M, Leversha MA, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Schultz N, Sander C, Lee W, Chan TA. The mutational landscape of adenoid cystic carcinoma. *Nature Genetics*. 2013 July; 45(7):791-8. PMID 23685749.
70. **Ho AS**, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG. Decision-making in the management of recurrent head and neck cancer. *Head & Neck*. 2014 Jan; 36(1):144-51. PMID 23471843.
71. Nixon IJ, **Ho AS**, Shah JP. Medullary cancer of the thyroid gland. *Otorinolaringologia*. 2013 June; 63(2):75-83.
72. **Ho AS**, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, Fischbein NJ, Quon A, Le QT, Pinto HA, Fee WE Jr, Sunwoo JB, Sirjani D, Hara W, Yao M. Impact of PET/CT surveillance at 12 and 24 months for detecting head and neck cancer recurrence. *Cancer*. 2013 Apr 1; 119(7):1349-56. PMID 23225544.
73. **Ho AS**, Turcan S, Chan TA. Epigenetic therapy – use of deacetylases and demethylating agents in cancer management. *OncoTargets and Therapy*. 2013 Mar 20; 6:223–232. PMID 23569385.
74. Agrawal N, Jiao Y, Sausen M, Leary R, Bettgowda C, Roberts NJ, Bhan S, **Ho AS**, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW. Exomic sequencing of MTC reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. *J Clinical Endocrinology and Metabolism*. 2013 Feb; 98(2):E364-9. PMID 23264394.
75. Damrose EJ, **Ho AS**. Endoscopic cricopharyngeal myotomy. *Operative Techniques in OHNS*. 2012 Jun; 23: 144-148.
76. **Ho AS**, Kaplan MJ, Fee WE, Yao M, Sunwoo JB, Hwang PH. Targeted endoscopic salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma. *International Forum of Allergy and Rhinology*. 2012 Mar; 2(2): 166-173. PMID 22170783.
77. **Ho AS**, Morzaria S, Damrose EJ. Management of intraoral needle migration into the posterior cervical space. *Auris Nasus Larynx*. 2011 Dec; 38(6): 747-9. PMID 21324618.
78. Barnes M\*, **Ho AS\***, Malhotra PS, Koltai PJ, Messner AH. The use of botulinum toxin for pediatric cricopharyngeal achalasia. *International Journal of Pediatric Otorhinolaryngology*. 2011 Jun; 75(6): 830-4. PMID 21972448 [\*co-first authors]
79. **Ho AS**, Morzaria S, Damrose EJ. Carbon dioxide laser-assisted endoscopic cricopharyngeal myotomy with primary mucosal closure. *Annals of Otolaryngology, Rhinology, and Laryngology*. 2011 Jan; 120(1): 33-39. PMID 21370678.

#### 2000 – 2010

80. **Ho AS**, Huang X, Cao H, Christman-Skieller C, Le QT, Koong AC. Circulating miR-210 is a novel hypoxia marker in pancreatic cancer. *Translational Oncology*. 2010 Apr; 3(2): 109-13. PMID 20360935 [cover article]

81. Kassis JN, Virador VM, Guancial EA, Kimm D, **Ho AS**, Mishra M, Chuang EY, Cook J, Gius D, Kohn EC. Genomic and phenotypic analysis reveals a key role for CCN1 (Cyr61) in BAG-3 – modulated adhesion and invasion. *Journal of Pathology*. 2009 Aug; 218(4): 495-504. PMID 19402132.
82. **Ho AS**, Aleshi P, Cohen SE, Koltai PJ, Cheng AJ. Airway management in Nager Syndrome. *International Journal of Pediatric Otorhinolaryngology*. 2008 Dec; 72(12): 1885-1888. PMID 18947886.
83. **Ho AS**, Koltai PJ. Pediatric tracheal stenosis. *Otolaryngologic Clinics of North America*. 2008 Oct; 41(5): 999-1021. PMID 18775347.
84. Sun L, Huang L, Nguyen P, Bisht KS, Bar-Sela G, **Ho AS**, Bradbury CM, Yu W, Cui H, Lee S, Trepel JB, Feinberg AP, Gius D. DNA Methyltransferase 1 and 3B activate Bag-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. *Cancer Research*. 2008 Apr 15; 68(8): 2726-2735. PMID 18413740.
85. Mowry SE, **Ho A**, Lotempio MM, Sadeghi A, Blackwell KE, Wang MB. Quality of life in advanced oropharyngeal carcinoma following chemoradiation versus surgery and radiation. *Laryngoscope*. 2006 Sep; 116(9): 1589-1593. PMID 20039175.
86. Gius D, Bradbury CM, Sun L, Awwad RT, Huang L, Smart DD, Bisht KS, **Ho AS**, Nguyen P. The epigenome as a molecular marker and target. *Cancer*. 2005 Sep 7; 104(9): 1789-1793. PMID 16149092.
87. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, Young L, Brandenburg SA, Hu Y, Bisht KS, **Ho AS**, Mattson D, Sun L, Munson PJ, Chuang EY, Mitchell JB, Feinberg AP. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. *Cancer Cell*. 2004 Oct; 6(4): 361-371. PMID 15488759.
88. **Ho AS**. Nicotine and caffeine as defensive agents against Parkinson Disease. *Nutrition Bytes*. 2002; Vol 8: No 2, Art 3.
89. **Ho AS**, Monuki E, Walsh CA. A potential genetic basis for schizencephaly. *The Harvard Brain*. 2001; Vol 8: 4-21.

#### INVITED EDITORIAL COMMENTARY

1. **Ho AS**, Sacks WL, Zumsteg ZS. Revisiting the prognostic significance of grade in papillary thyroid carcinoma. *Annals of Surgical Oncology*. 2020 Dec;27(Suppl 3):852-853. PMID 32864730.
2. Mallen-St. Clair J, **Ho AS**. AJCC-8th edition staging – An improvement in prognostication in HPV-associated oropharyngeal cancer? *Annals of Translational Medicine*. 2019 Mar;7(Suppl 1):S10. PMID 31032291.

#### LETTERS TO THE EDITOR

1. Marti JL, Morris LGT, **Ho AS**. Reply to: Selective history of radioactive iodine in medicine: inexactitudes no longer. *European Journal of Surgical Oncology*. 2018 Sep 7. pii: S0748-7983(18)31301-5. PMID 30224249.
2. Epstein JB, Song P, **Ho A**, Larian B, Asher A, Bensadoun RJ. Management of radiation-induced mucosal necrosis with photobiomodulation therapy. *Support Care Cancer* 2018 Aug;26(8): 2493. PMID 29728844.
3. Marti JL, Morris LGT, **Ho AS**. Reply to: Radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm? *European Journal of Surgical Oncology*. 2017 Sep;43(9): 1804. PMID 28756886.

#### TEXTBOOKS

1. *Multidisciplinary Care of the Head and Neck Cancer Patient*. Maghami E and **Ho AS**, ed. New York: Springer, 2018.

#### BOOK CHAPTERS

1. Kahue C, Kakarala K, **Ho AS**. Head and neck cancer. In *Cummings Review of Otolaryngology*. 2<sup>nd</sup> Edition. Lin HW, Roberts DS, Harris JP, ed. Philadelphia: Elsevier [submitted].
2. Zumsteg ZS, Lu DJ, **Ho AS**. Chapter 33. Definitive external beam radiation therapy for oral cavity cancer. In *Oral Cancer: Evaluation, Therapy, and Rehabilitation*. Fakhry C, Pitman KT, Kiess AP, Eisele DW, ed. New York: Thieme, 2020.
3. **Ho AS**, Maghami E. Chapter 5. Surgical Challenges in Head and Neck Cancer. In *Multidisciplinary Care of the Head and Neck Patient*. 1<sup>st</sup> Edition. Maghami E and Ho AS, ed. New York: Springer, 2018.
4. **Ho AS**, Ganly I. Chapter 57. Cancer of the oral cavity. In *Textbook of General Surgical Oncology*. 2<sup>nd</sup> Edition. Morita SY and Balch CM, ed. New York: McGraw-Hill Education, 2017.
5. **Ho AS**, Patel SG. Chapter 59. Tumors of the nose and sinuses. In *Textbook of General Surgical Oncology*. 2<sup>nd</sup> Edition. Morita SY and Balch CM, ed. New York: McGraw-Hill Education, 2017.
6. **Ho AS**, Kakarala K, Wieland A. Head and neck cancer. In *Cummings Review of Otolaryngology*. 1<sup>st</sup> Edition. Lin HW, Roberts DS, Harris JP, ed. Philadelphia: Elsevier, 2016.

7. **Ho AS**, Zanation AM, Ganly I. Chapter 82. Malignancies of the paranasal sinus. In *Cummings Otolaryngology: Head and Neck Surgery*. 6<sup>th</sup> Edition. Flint PW, ed. Philadelphia: Elsevier, 2015.
8. **Ho AS**. Chapter 22. Malnutrition in head and neck cancer. In *Self-Assessment in Head and Neck Surgery and Oncology*. O'Neil JP and Shah JP, ed. Philadelphia: Elsevier, 2014.
9. **Ho AS**, Morris LG. Chapter 10. Role of PET/CT scanning in head and neck cancer. In *Recent Advances in Otolaryngology-Head & Neck Surgery*. Second Edition. Lalwani AK and Pfister MH, ed. London: Jaypee Brothers, 2013.
10. **Ho AS**, Yao M. Chapter 16. Treatment planning considerations. In *Head and Neck Cancer: Current Perspectives, Advances, and Challenges*. Radosevich JA, ed. New York: Springer, 2013.

## SELECTED ABSTRACTS

1. Nguyen AT, Luu M, Mallen-St. Clair J, Mita A, Scher K, Lu DJ, Shiao SL, **Ho AS**, Zumsteg ZS. Survival impact of transoral robotic surgery in early-stage oropharyngeal cancer. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. IJORBP 108(3);E416-417. November 01, 2020.
2. Anderson E, Luu M, Nguyen AT, Mallen-St. Clair J, Scher K, Mita A, **Ho AS**, Zumsteg ZS. The variable association of grade with survival among different head and neck cancer subsites. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. IJORBP 108(3);E837-E838. November 01, 2020.
3. Nguyen AT, **Ho AS**, Luu M, Mita A, Scher K, Lu DJ, Mallen-St. Clair J, Walgama E, Zumsteg ZS. Re-examining the changes in the pathologic nodal classification systems for HPV(+) and HPV(-) oropharyngeal cancer. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. IJORBP 108(3);E803. November 01, 2020.
4. Lu DJ, Luu M, Nguyen AT, Scher K, Mallen-St. Clair J, Mita A, Shiao SL, **Ho AS**, Zumsteg ZS. The role of concomitant chemoradiotherapy on survival in AJCC 7th Edition T1-2N1 oropharyngeal carcinoma in the HPV era. Poster Theater Presentation. IJROBP 106(5)1128-29. April 01, 2020.
5. Lu DJ, Luu M, Nguyen AT, Scher K, Mallen-St. Clair J, Mita A, Shiao SL, **Ho AS**, Zumsteg ZS. Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. San Antonio, TX. IJORBP 105(1);E425. September 01, 2019.
6. Nguyen AT, Luu M, Lu DJ, Hamid O, Mallen-St. Clair J, Gharavi N, **Ho AS**, Zumsteg ZS. Association of quantitative metastatic lymph node burden with survival in Merkel Cell Carcinoma. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. San Antonio, TX. IJORBP 105(1);E800. September 01, 2019.
7. Yoshida EJ, Luu M, Mallen-St. Clair J, Mita A, Scher K, Lu DP, Nguyen A, Shiao SL, **Ho AS**, Zumsteg ZS. Stage I HPV-positive oropharyngeal cancer: should all patients receive similar treatments? American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. San Antonio, TX. IJORBP 105(1);E431-432. September 01, 2019.
8. Anderson E, Luu M, Nguyen AT, Mallen-St. Clair J, Scher K, Mita A, **Ho AS**, Zumsteg ZS. Correlation of pathologic tumor grade with survival in oral cavity squamous cell carcinoma. *Journal of Clinical Oncology*. 38:15\_suppl. E18557. May 25, 2020.
9. Barrios L, Luu M, Chen I, Melany M, Ali N, Patio C, Kim J, Chen Y, Fan X, Mallen-St. Clair J, Braunstein GD, Sacks WL, Zumsteg ZS, **Ho AS**. Mortality risk spectrum across aggressive variants of papillary thyroid carcinoma: prognosis and response to EBRT. American Thyroid Association Annual Meeting. Poster Presentation. October 2019.
10. Sittig MP, Yoshida EJ, Lu D, Anderson E, Mallen-St. Clair J, Shiao SL, **Ho AS**, Zumsteg ZS. Impact of primary payer on survival in patients <65 years of age with localized head and neck cancer treated with definitive radiotherapy. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. IJROBP 102(3);E312-313. San Antonio, TX. October 2018.
11. Lu D, Luu M, Mita A, Scher K, Shiao S, Sittig M, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. HPV-associated oropharyngeal cancer among elderly patients: dramatically increased prevalence and clinical implications. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. *IJROBP*. 102:3, Supplement. E284-E285. Poster Presentation. San Antonio, TX. November 2018.
12. Yoshida EJ, **Ho AS**, Shiao SL, David J, Mita A, Scher K, Zumsteg, ZS. Survival impact of treatment at high-volume facilities for nasopharyngeal carcinoma. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. San Antonio, TX. IJROBP 99(2);E384. October 2018.

13. Marcadis AR, Marti JL, **Ho AS**, Valderrabano P, Tepe J, Swartzwelder CE, Byrd S, Untch BR, Shaha AR, Xu B, Lin O, Ghossein RA, Wong RJ, Morris LGT. Inter-institutional variation in predictive value of the Thyroseq v2 genomic classifier for thyroid nodules. American Association of Endocrine Surgeons Annual Meeting. Oral Presentation. Durham, NC. May 2018.
14. Anderson E, Yoshida EJ, Mita A, Scher K, Mallen-St. Clair J, **Ho AS**, Zumsteg ZS. Survival in Asian Americans with nasopharyngeal cancer undergoing definitive radiotherapy. Multidisciplinary Head and Neck Cancer Symposium. Poster Presentation. Scottsdale, AZ. IJROBP 100(5);1353-54. February 2018.
15. **Ho AS**, Kim S, Tighiouart M, Gudino C, Mita A, Scher K, Epstein JB, Ali N, Patio CD, Laury A, Prasad R, Thompson HD, Strouss AE, Prasad R, Mallen-St. Clair J, Van Eyk JE, Shiao SL, Zumsteg ZS. Survival impact of treatment interval delays in head and neck cancer. Multidisciplinary Head and Neck Cancer Symposium. Poster Presentation. Scottsdale, AZ. IJROBP 100(5);1322-23. February 2018.
16. Kimura B, Mita A, **Ho AS**, Sacks W. Vocal cord paralysis and overt hypothyroidism due to metastatic colon adenocarcinoma to the thyroid gland. American Thyroid Association (ATA) Annual Meeting. Poster Presentation. Victoria, British Columbia, Canada. September 2017.
17. Robinson A, Laury A, Parker SJ, Shiao SL, Knudsen B, Zumsteg ZS, Van Eyk JE, **Ho AS**. Proteomic stratification of HPV(+) oropharyngeal squamous cell carcinoma identifies targets in insulin receptor signaling within nonresponders. AACR-AHNS Head and Neck Cancer Conference. Poster Presentation. San Diego, CA. April 2017.
18. **Ho AS**, Kim S, Tighiouart M, Gudino C, Mita A, Scher K, Prasad R, Shiao SL, Ali N, Patio C, Zumsteg ZS. Metastatic lymph node burden and survival in head and neck cancer. Combined Otolaryngology Spring Meeting (COSM). Poster Presentation. San Diego, CA. April 2017.
19. Sacks WL, Zumsteg ZS, Melany ML, Chen IE, Laury AR, Bose S, Braunstein GD, **Ho AS**. Management trends in active surveillance of papillary thyroid microcarcinoma. American Thyroid Association (ATA) Annual Meeting. Poster Presentation. Denver, CO. September 2016.
20. Zumsteg ZS, Cook-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, Jeon C, Goodman MT, **Ho AS**. The increasing incidence of oropharyngeal cancer among elderly patients in the United States. American Society of Therapeutic Radiation Oncology (ASTRO) Annual Mtg. Poster Presentation. Boston, MA. IJROBP 96(2); E379. September 2016.
21. Zumsteg ZS, Lok B, **Ho AS**, Riaz N, Shiao SL, McBride S, Tsai J, Baxi S, Sherman E, Lee NY. The toxicity and efficacy of concomitant chemoradiotherapy in elderly patients with oropharyngeal carcinoma in the intensity modulated radiotherapy era. American Society of Clinical Oncology (ASCO) Annual Mtg. Poster Presentation. Chicago, IL. June 2016.
22. Sacks WL, Bose S, Wong R, Braunstein GD, **Ho AS**. Impact of Afirma GEC on cytopathology diagnosis and thyroidectomy incidence. 15<sup>th</sup> International Thyroid Congress/American Thyroid Association 85<sup>th</sup> Annual Meeting. *Thyroid*. Oct 2015, 25(S1): A-325. Poster 822. Orlando, FL. October 2015.
23. Marti JL, **Ho AS**, Avadhani V, Donatelli L, Niyogi S, Wang B, Shaha AR, Ghossein RA, Lin O, Morris LGT. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. Society of Surgical Oncology (SSO) Annual Cancer Symposium. Oral Presentation. Houston, TX. March 2015.
24. **Ho AS**, Wang L, Palmer F, Yu C, Toset A, Patel SG, Kattan MW, Tuttle RM, Ganly I. Postoperative nomogram for predicting cancer-specific mortality in medullary thyroid cancer. American Thyroid Association (ATA) Annual Meeting. Oral Presentation. Coronado, CA. October 2014.
25. **Ho AS**, Nixon IJ, Palmer FA, Wang LY, Patel SG, Ganly I, Wong RJ, Davies LD, Morris LGT. Overdiagnosis of subclinical papillary thyroid cancers leads to spurious improvements in survival rates. IFHNOS 5<sup>th</sup> World Congress/AHNS Annual Meeting. Oral Presentation. New York, NY. July 2014.
26. **Ho AS**, Donatelli LA, Niyogi S, Fish SA, Fagin JA, Shaha AR, Shah JP, Wong RJ, Ghossein RA, Lin O, Morris LGT. Performance of the Afirma Gene Expression Classifier at a thyroid cancer referral center. IFHNOS 5<sup>th</sup> World Congress/AHNS Annual Meeting. Oral Presentation. New York, NY. July 2014.
27. Meyer A, **Ho AS**, Riaz N, Rahmati R, Linkov G, Mohebati A, Kraus DK, McCarthy C, Lee NJ. Outcomes in recurrent head and neck cancer after salvage surgery with and without flap reconstruction with postoperative reirradiation. Combined Otolaryngology Spring Meetings (COSM). Poster Presentation. Las Vegas, NV. May 2014.
28. **Ho AS**, Nixon IJ, Palmer FL, Shah JP, Tuttle RM, Ganly I. Comparative assessment of preoperative and postoperative risk recurrence in medullary thyroid cancer. American Thyroid Association (ATA) Annual Meeting. Poster Presentation. San Juan, Puerto Rico. October 2013.



29. **Ho AS**, Palmer FL, Shah JP, Tuttle RM, Ganly I. Dynamic risk stratification for recurrence in medullary thyroid cancer. American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Annual Meeting. Poster Presentation. Vancouver, Canada. Sept 2013.
30. **Ho AS**, Sarti E, Wang H, Jain KS, Lin O, Nixon IJ, Shaha AR, Shah JP, Tuttle RM, Ghossein R, Wong RJ, Morris LG. Malignancy rate and substratification efficacy in thyroid nodules classified as atypia of undetermined significance. Combined Otolaryngology Spring Meetings (COSM). Oral Presentation. Orlando, FL. April 2013.
31. **Ho AS**, Sarti E, Wang H, Jain KS, Lin O, Nixon IJ, Shaha AR, Shah JP, Tuttle RM, Ghossein R, Morris LG. Elevated rate of malignancy in thyroid FLUS/AUS nodules. New York Head and Neck Society Proffered Paper Session. Oral Presentation. New York, NY. March 2013. [Second Place Award].
32. Katabi N, **Ho AS**, Ho AL, Ganly I, Ghossein R. Adenoid cystic carcinoma of salivary glands: clinicopathologic study with emphasis on Myb protein expression. 102<sup>nd</sup> U.S. and Canadian Academy of Pathology (USCAP) Annual Meeting. Poster Presentation. Baltimore, MD. March 2013.
33. Wang H, **Ho AS**, Morris LG, Lin O. FLUS in thyroid FNA: malignancy rate and value of substratification. 102<sup>nd</sup> U.S. and Canadian Academy of Pathology (USCAP) Annual Meeting. Poster Presentation. Baltimore, MD. March 2013.
34. **Ho AS**, Jain KS, Lin O, Shaha AR, Shah JP, Tuttle RM, Morris LG. Incidence of malignancy in thyroid nodules classified as AUS. Triological Society Combined Sections Meeting. Oral Presentation. Scottsdale, AZ. January 2013.
35. **Ho AS**, Yu C, Toset A, Palmer FL, Shah JP, Patel S, Kattan MW, Tuttle RM, Ganly I. A predictive model for medullary thyroid cancer recurrence. 8<sup>th</sup> International Conference on Head & Neck Cancer. Oral Presentation. Toronto, Canada. July 2012.
36. **Ho AS**, Tsao G, Yao M. PET/CT in the routine post-treatment surveillance of head and neck cancer. 8<sup>th</sup> International Conference on Head and Neck Cancer. Poster Presentation. Toronto, Canada. July 2012. [Honorable Mention]
37. **Ho AS**, Kaplan MJ, Fee WE, Yao M, Sunwoo JB, Hwang PH. Targeted endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma. AAO-HNS Annual Meeting. Oral Presentation. San Francisco, CA. Sept 2011.
38. **Ho AS**, Kaplan MJ, Fee WE, Yao M, Sunwoo JB, Hwang PH. Endoscopic salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma. Stanford OHNS Resident Research Symposium. Oral Presentation. Palo Alto, CA. June 2011.
39. **Ho AS**, Barnes MA, McKenney JK, Malhotra PS, Cheng AJ. Pediatric giant juvenile xanthogranuloma in the parotid gland. Triological Society Combined Sections Meeting. Poster Presentation. Scottsdale, AZ. Jan 2011.
40. Morzaria S, **Ho AS**, Damrose EJ. CO<sub>2</sub> laser assisted endoscopic CP myotomy with primary closure of the mucosal defect. Voice Foundation 39<sup>th</sup> Annual Symposium: Care of the Professional Voice. Oral Presentation. Philadelphia, PA. June 2010.
41. **Ho AS**, Barnes MA, Malhotra PS, Koltai PJ, Messner AH. The use of botulinum toxin for pediatric cricopharyngeal achalasia. Combined Otolaryngology Spring Meetings (COSM). Poster Presentation. Las Vegas, NV. April 2010.
42. **Ho AS**, Huang X, Cao H, Le QT. miR-210 as a novel hypoxia marker in head and neck cancer. American Academy of Otolaryngology-Head & Neck Surgery (AAO-HNS) Annual Meeting. Poster Presentation. San Diego, CA. October 2009.
43. **Ho AS**, Huang X, Cao H, Le QT. miR-210 correlates with CA9 staining and is a novel hypoxia marker in head and neck cancer. Bay Area Resident Research Symposium (BARRS). Oral Presentation. Berkeley, CA. June 2009.
44. **Ho AS**, Huang X, Cao H, Koong AC, Le QT. Detection of circulating hypoxia-regulated miR-210 in pancreatic cancer pts. *Journal of Clinical Oncology* 27:15s (suppl; abstr 4624). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Mtg. Orlando, FL. May 2009.
45. **Ho AS**, Aleshi P, Cohen SE, Koltai PJ, Cheng AJ. Airway management in Nager Syndrome. *Laryngoscope* 119: Issue Supplement S1, pg. S179, 2009. Western Section Triological Meeting. Poster Presentation. Las Vegas, NV. Jan 2009.
46. **Ho AS**, Damrose E. CO<sub>2</sub> laser-assisted endoscopic cricopharyngeal myotomy. Combined Otolaryngology Spring Meetings (COSM). Poster Presentation. Orlando, FL. May 2008.
47. **Ho AS**, Gius D. DNMT may impart resistance against agents that induce oxidative stress including ionizing radiation, H<sub>2</sub>O<sub>2</sub>, and hypoxia. Radiological Society of North America (RSNA) Annual Meeting. Oral Presentation. Chicago, IL. Nov 2005.
48. **Ho AS**, Sun L, Bradbury CM, Bisht KS, Mattson D, Gius D. A novel mechanism of epigenetic regulation in the BAG gene family. *Proceedings of the American Association for Cancer Research*. Volume 46: 2738. Poster Presentation. 96th AACR Annual Mtg. Anaheim, CA. April 2005.
49. **Ho AS**, Sun L, Bradbury CM, Bisht KS, Mattson D, Gius D. Epigenetic regulation of the BAG gene family. HHMI-NIH Science Day. Oral Presentation. Bethesda, MD. May 2004.

50. **Ho AS**, Bradbury C, Gius D. Molecular targeting of thioredoxin reductase to enhance tumor stress responses. 6<sup>th</sup> Joint Conference of the American Academy of Cancer Research/Japanese Cancer Association: Advances in Cancer Research Conference. Waikoloa, HI. January 2004.
51. **Ho AS**, Gessessee H, Lee E, Srivatsan ES, Wang MB. Reduction of head and neck squamous cell carcinoma viability using a p16 tumor suppressor Trojan peptide. *Journal of Investigative Medicine*. Volume 50:1. American Federation for Medical Research Western Regional Meeting. Oral Presentation. January 2003.

### GRAND ROUNDS AND INVITED LECTURES

1. **Ho AS**, Tuttle RM. Thyroid nodules. Breakout Session Moderator. American Thyroid Association (ATA) Alliance for Thyroid Patient Health Forum. October 2021.
2. **Ho AS**. Managing HPV(+) patients. Oral Presentation. Advanced Otolaryngology Conference. Cedars-Sinai Medical Center. Los Angeles, CA. March 2021.
3. **Ho AS**, Tuttle RM, Yeh M. Meet the Professor: Current status of active surveillance in the U.S. Oral Presentation. American Thyroid Association Year in Thyroidology: A Virtual Experience. February 2021.
4. **Ho AS**. Advanced Larynx Cancer. Oral Presentation. Otolaryngology Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. January 2021.
5. **Ho AS**. Do I have cancer in my mouth? Otolaryngology 2021 Conference. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. January 2021.
6. **Ho AS**. Lumpers vs. Splitters – the current state of aggressive papillary thyroid carcinoma. Oral Presentation. Endocrinology Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. December 2020.
7. **Ho AS**, Bloom G. Adult thyroid cancer. Breakout Session Moderator. American Thyroid Association (ATA) Alliance for Thyroid Patient Health Forum. November 2020.
8. **Ho AS**. When is active surveillance the right decision? Reconciling divergent opinions on treatment. Oral Presentation. 23<sup>rd</sup> International Thyroid Cancer Survivors' Conference. October 2020.
9. **Ho AS**. Surgical complications after thyroidectomy. Oral Presentation. 23<sup>rd</sup> International Thyroid Cancer Survivors' Conference. October 2020.
10. **Ho AS**. Hemorrhagic lingual thyroid managed with transoral robotic surgery. Oral Presentation. Eerie ENT Conference. Cedars-Sinai Medical Center. Los Angeles, CA. October 2020.
11. **Ho AS**. Management of oral malignancies. Oral Presentation. Multidisciplinary Research Conference. John Wayne Cancer Institute. Santa Monica, CA. April 2020.
12. **Ho AS**. Oral Cancer Update. Oral Presentation. Torrance Memorial Medical Center. Torrance, CA. March 2020.
13. **Ho AS**. Thyroid cancer management in 2020. Oral Presentation. Torrance Memorial Medical Center. Torrance, CA. February 2020.
14. **Ho AS**. Parotid neoplasm update. Oral Presentation. Hollywood Presbyterian Medical Center. Los Angeles, CA. February 2020.
15. **Ho AS**. Spectrum of oral cavity malignancies. Alpha Omega Dental Society. Oral Presentation. Los Angeles, CA. January 2020.
16. **Ho AS**. Grantwriting Panel. Clinical Scholars Workshop. Panelist. Los Angeles, CA. January 2020.
17. **Ho AS**. Head and Neck Cancer Essential Update Panel. Advances in Otolaryngology Conference. Los Angeles Society of Otolaryngology. Panelist. Los Angeles, CA. January 2020.
18. **Ho AS**. Oropharynx panel. Annual Conference of the Israeli Society of Head and Neck Surgery and Oncology (ISHNOS). Panelist. Jerusalem, Israel. November 2019.
19. **Ho AS**. Calibrating treatment paradigms for head and neck cancer in the era of deintensification (keynote lecture). Annual Conference of the Israeli Society of Head and Neck Surgery and Oncology (ISHNOS). Oral Presentation. Jerusalem, Israel. November 2019.
20. **Ho AS**. Intraoperative nerve monitoring in thyroid surgery: why, when, and how. Annual Conference of the Israeli Society of Head and Neck Surgery and Oncology (ISHNOS). Panelist. Jerusalem, Israel. November 2019.
21. **Ho AS**. Parallels between low-risk prostate cancer and thyroid cancer (keynote lecture). Annual Conference of the Israeli Society of Head and Neck Surgery and Oncology (ISHNOS). Oral Presentation. Jerusalem, Israel. November 2019.

22. **Ho AS.** Roundtable: AJCC Staging. Annual Conference of the Israeli Society of Head and Neck Surgery and Oncology (ISHNOS). Panelist. Jerusalem, Israel. November 2019.
23. **Ho AS.** Active surveillance for thyroid cancer: lessons to be shared. New Therapeutics in Oncology: The Road to Personalized Medicine. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. November 2019.
24. **Ho AS.** Calibrating treatment paradigms for HPV+ oropharyngeal cancer. Medical Oncology Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. June 2019.
25. **Ho AS.** Quickshot Oral Presentations. American Head and Neck Society (AHNS) Annual Meeting. Moderator. Austin, TX. May 2019.
26. **Ho AS.** Genetic and immunologic hallmarks of recurrent/metastatic adenoid cystic carcinoma. American Head and Neck Society (AHNS) Annual Meeting. Oral Presentation. Austin, TX. May 2019.
27. **Ho AS.** Thyroid Cancer Panel. American Association of Clinical Endocrinology (AACE) 28<sup>th</sup> Annual Meeting. Panelist. Los Angeles, CA. April 2019.
28. **Ho AS.** Considerations for active surveillance: when to watch and when to wait. American Thyroid Association Spring Satellite Symposium. Oral Presentation. New Orleans, LA. March 2019.
29. **Ho AS.** Do I have cancer in my mouth? Otolaryngology 2019 Conference. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. March 2019.
30. **Ho AS.** Social media implications for the AHNS Endocrine Section. AHNS Endocrine Section Retreat. Oral Presentation. Boston, MA. Feb 2019.
31. **Ho AS.** Indications for transoral robotic surgery (TORS) in oropharyngeal cancer. Department of Radiation Oncology. Resident Lecture Series. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. January 2019.
32. **Ho AS.** Evolving management of oral malignancies. Division of Dentistry Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. November 2018.
33. **Ho AS.** Low-risk prostate vs. thyroid cancer: lessons to be shared. Endocrine Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. May 2018.
34. **Ho AS.** Active surveillance of thyroid microcarcinoma panel. International Thyroid Oncology Group (ITOG) Annual Meeting. Moderator. Los Angeles, CA. April 2018.
35. **Ho AS.** HPV(+) throat cancer. Telemundo 52 La Feria de la Salud Health Fair. Oral Presentation. Los Angeles, CA. March 2018.
36. **Ho AS.** Do I have cancer in my mouth? ENT for the non-ENT Provider Conference. Oral Presentation. Los Angeles, CA. [March 2018].
37. **Ho AS.** New ATA Guidelines and Staging for Thyroid Cancer. 86<sup>th</sup> Midwinter Conference – Research Study Club of Los Angeles. Oral Presentation. Los Angeles, CA. Jan 2018. \*Selected for Audio Digest publication.
38. **Ho AS.** Conversations About Cancer. Samuel Oschin Comprehensive Cancer Institute Event Series. Panelist. Los Angeles, CA. October 2017.
39. **Ho AS.** Thyroid case review. Cedars-Sinai Resident Education Series. Oral Presentation. Los Angeles, CA. October 2017.
40. **Ho AS.** Cancers that don't require surgery at all: micro-PTC observation. Low-risk Thyroid Cancer Workshop. American Thyroid Association Annual Meeting. Oral Presentation. Victoria, British Columbia, Canada. October 2017.
41. **Ho AS.** The modern thyroid surgeon's role in the era of guideline-driven management. Department of Surgery Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. October 2017.
42. **Ho AS.** The calibrated thyroid surgeon: how ATA has modernized thyroid cancer management. Thyroid Cancer Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. September 2017.
43. **Ho AS.** Head and Neck Cancer Program Update. Cedars-Sinai Board of Directors Meeting. Oral Presentation. Los Angeles, CA. June 2017.
44. **Ho AS.** The new ATA Guidelines on thyroid cancer – how they will change your practice. Los Angeles Society of Otolaryngology-Head and Neck Surgery. Oral Presentation. Los Angeles, CA. May 2017.
45. **Ho AS.** Management of oral cancer. Los Angeles Dental Society. Oral Presentation. Los Angeles, CA. April 2017.
46. **Ho AS.** Do I have cancer in my mouth? Otolaryngology 2017 Conference. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. March 2017.

47. **Ho AS.** Head and neck cancer in 2016: the good, the bad, and the ugly. OR Nursing/Anesthesia Grand Rounds In-Service. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. December 2016.
48. **Ho AS.** Active surveillance for papillary thyroid microcarcinomas. 19<sup>th</sup> International Thyroid Cancer Survivors' Conference. Oral Presentation. Los Angeles, CA. October 2016.
49. **Ho AS.** Anaplastic thyroid cancer: management principles for an unprincipled disease. Advances in the Management of Thyroid Cancer Conference. Oral Presentation. Los Angeles, CA. October 2016. \*Selected for Audio Digest publication.
50. **Ho AS.** Thyroid Cancer Tumor Board. Advances in the Management of Thyroid Cancer Conference. Panelist. Los Angeles, CA. October 2016.
51. **Ho AS.** Head and Neck Tumor Board Update. Southern California Head and Neck Symposium. UCLA Medical Center. Oral Presentation. Los Angeles, CA. June 2016.
52. **Ho AS.** Mutational characterization of adenoid cystic carcinoma. Jatin Shah Festschrift – Scientific Symposium. Oral Presentation. Memorial Sloan Kettering Cancer Center. New York, NY. June 2016.
53. **Ho AS.** Molecular drift: Collateral effects of molecular testing on indeterminate thyroid nodules. Division of Endocrinology Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. May 2016.
54. **Ho AS.** Head and neck cancer in 2016: the good, the bad, and the ugly. Department of Surgery Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. January 2016.
55. **Ho AS.** HPV+ head and neck malignancies: evolving insights into prognosis, treatment goals, and patient care. Department of Medicine Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. November 2015.
56. **Ho AS.** Introductory Overview and Tumor Board. Southern California Head and Neck Symposium. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. November 2015.
57. **Ho AS.** Anaplastic thyroid carcinoma: management principles for an unprincipled disease. Endocrine Grand Rounds. Harbor-UCLA Medical Center. Oral Presentation. Los Angeles, CA. September 2015.
58. **Ho AS.** HPV and head & neck cancer: new insights on prognosis and management. Medical Oncology Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. July 2015.
59. Marti JL, **Ho AS,** Avadhni V, Donatelli L, Niyogi S, Wang B, Shaha AR, Ghossein RA, Lin O, Morris LGT. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. New York Thyroid Club. Hackensack University Medical Center. Oral Presentation. Hackensack, NJ. April 2015.
60. **Ho AS.** Laryngectomy and tracheostomy management. Department of Emergency Medicine Grand Rounds. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. March 2015.
61. **Ho AS.** Expert Panel Roundtable – Head and Neck. Annual ENT for the PA Conference. Society of Physician Assistants in Otorhinolaryngology-Head & Neck Surgery. Oral Presentation. Newport Beach, CA. March 2015.
62. **Ho AS.** Parapharyngeal space tumor management. Annual ENT for the PA Conference. Society of Physician Assistants in Otorhinolaryngology-Head & Neck Surgery. Oral Presentation. Newport Beach, CA. March 2015.
63. **Ho AS.** TCGA papillary thyroid cancer summation. Thyroid Cancer Grand Rounds. Oral Presentation. Cedars-Sinai Medical Center. Los Angeles, CA. February 2015.
64. **Ho AS.** Resident Absite: thyroid cancer review. Cedars-Sinai Medical Center. Oral Presentation. Los Angeles, CA. January 2015.
65. **Ho AS.** Advances in head and neck cancer management. Third Annual Experimental Therapeutics in Oncology Conference. Oral Presentation. Cedars-Sinai Medical Center. Los Angeles, CA. November 2014. \*Selected for Audio Digest publication.
66. **Ho AS.** Active surveillance for papillary thyroid microcarcinoma. Endocrine Clinical Conference. Harbor-UCLA Medical Center. Oral Presentation. Torrance, CA. October 2014.
67. **Ho AS.** Surgery research in head and neck cancer. SoCal HNC Meeting – University of California San Diego. Oral Presentation. San Diego, CA. September 2014.
68. **Ho AS.** Thyroid cancer case review. Cedars-Sinai Resident Education Series. Oral Presentation. Los Angeles, CA. August 2014.
69. **Ho AS.** Active surveillance for micropapillary thyroid carcinomas: Addressing overdiagnosis and overtreatment. Cedars-Sinai Thyroid Cancer Grand Rounds. Oral Presentation. Los Angeles, CA. July 2014.
70. **Ho AS.** The rising epidemic in HPV+ oropharyngeal cancers. Board of Governors Healthcare College. Oral Presentation. Los Angeles, CA. May 2014.

71. **Ho AS.** Endoscopic skull base surgery: indications and limitations. Cedars-Sinai Dept. of Surgery Grand Rounds. Oral Presentation. Los Angeles, CA. April 2014.
72. **Ho AS.** Adenoid cystic carcinoma genomics summation. International Rare Cancers Initiative (IRCI) Head & Neck/Salivary Gland Section. American Society of Clinical Oncology (ASCO) Annual Meeting. Oral Presentation. Chicago, IL. June 2013.
73. **Ho AS.** Endoscopic skull base surgery: indications and limitations. Memorial Sloan-Kettering Head and Neck Grand Rounds. Oral Presentation. New York, NY. May 2013.
74. **Ho AS.** The mutational landscape of adenoid cystic carcinoma. Memorial Sloan-Kettering Head and Neck Grand Rounds. Oral Presentation. New York, NY. November 2012.
75. **Ho AS.** Salvage surgery for head and neck squamous cell carcinoma. Memorial Sloan-Kettering Head and Neck Grand Rounds. Oral Presentation. New York, NY. Feb 2012.
76. **Ho AS.** Transnasal endoscopic skull base surgery: Indications and limitations. Stanford Otolaryngology-Head & Neck Surgery Grand Rounds. Oral Presentation. Palo Alto, CA. June 2011.
77. **Ho AS,** Huang X, Cao H, Le QT. miR-210 correlates as a novel hypoxia marker in head and neck cancer. Stanford Otolaryngology-Head and Neck Surgery Resident Research Symposium. Oral Presentation. Palo Alto, CA. June 2009.

### SCIENTIFIC GRANT SUPPORT

- |                |   |
|----------------|---|
| 2020 – Present | <b>Translational Oncology Program Developmental Fund Award (\$50,000)</b><br>TP63 suppresses anti-tumor immunity in HPV+ squamous cancers. Role: PI.                            |
| 2018 – Present | <b>Cedars-Sinai Precision Health Grant (\$129,123)</b><br>Predictive markers for deleterious treatment breaks during head and neck cancer treatment. Role: PI.                  |
| 2017 – Present | <b>Donna and Jesse Garber Award for Cancer Research (\$50,000)</b><br>Immunologic characterization of HPV(+) HN malignancies. Role: PI.   |
| 2016 – Present | <b>Health Network Foundation Grant (\$10,000)</b><br>Immunologic characterization of HPV(+) HN malignancies. Role: PI.  |
| 2015 – Present | <b>Cedars-Sinai Research Institute – Head and Neck General Research Fund (\$62,500)</b><br>Proteomic and immunologic stratification of HPV(+) HN malignancies. Role: PI.        |
| 2015 – 2016    | <b>Clinical and Translational Science Institute (CTSI) Research Core Voucher Grant (\$9,873)</b><br>Immunologic stratification of HPV-positive head and neck cancers. Role: PI. |
| 2013 – 2015    | <b>Adenoid Cystic Carcinoma Research Foundation Grant (\$230,470)</b><br>Functionalizing the ACC genome via integrated genomic analyses. Role: Co-PI.                           |
| 2012 – 2014    | <b>AHNS/AAO-HNSF Young Investigator Research Development Award (\$40,000)</b><br>Mutational characterization of adenoid cystic carcinoma. Role: PI.                             |
| 2011 – 2014    | <b>NIH T32 Ruth Kirschstein National Research Service Award (\$50,000)</b><br>Mutational landscape of salivary and thyroid malignancies. Role: Grantee.                         |
| 2004 – 2006    | <b>HHMI-NIH Continuing Support Scholarship (\$78,000)</b><br>Role of <i>bag</i> family in transcriptional activation of head and neck malignancies. Role: Grantee.              |

### OTHER GRANT SUPPORT

- |             |  |
|-------------|--|
| 2003 – 2004 | <b>The California Endowment Foundation Project Grant (\$9,100)</b><br>Minority Health Conference: Bridging Cultures and Enhancing Care. Role: Principal Author.              |
| 2003 – 2004 | <b>UCLA Office of Academic Outreach and Enrichment Project Grant (\$10,000)</b><br>Minority Health Conference: Bridging Cultures and Enhancing Care. Role: Principal Author. |
| 1999 – 2000 | <b>Ronald McDonald House Charities Grant (\$13,500)</b><br>Harvard Chinatown Committee Computing Facility. Role: Principal Author.   |

### IRB PROTOCOLS

- |                |   |
|----------------|---|
| 2015 – Present | <b>Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma</b><br><b>Role: Principal Investigator.</b> <ul style="list-style-type: none"><li>• Proteomic/Immunologic characterization of HPV+ HNSCC treatment failures vs. successes.</li></ul> |
| 2015 – Present | <b>Active Surveillance of Papillary Thyroid Microcarcinoma</b>  |

**Role: Principal Investigator.**

- Evaluation of conservative, nonsurgical approach to small papillary thyroid carcinomas.
- ClinicalTrials.gov Identifier: NCT02609685

**ACADEMIC COMMITTEES**

2021 - Present	AHNS Endocrine Section Board
2021 - Present	Program Evaluation Committee, Cedars-Sinai Otolaryngology Residency Program
2021 - Present	Clinical Competency Committee, Cedars-Sinai Otolaryngology Residency Program
2019 – Present	AHNS Publications & Awards Service
2018 – Present	ATA Patient Affairs and Education Committee
2018 – 2019	Abstract Review Committee – 2019 AHNS Annual Meeting (Austin, TX)
2018 – 2019	Program Committee – 2019 ATA Spring Satellite Symposium (New Orleans, LA)
2017 – Present	AAO-HNS Endocrine Surgery Committee
2016 – Present	Cedars-Sinai Head and Neck Disease Research Group (DRG)
2015 – Present	Cedars-Sinai Head and Neck Disease Management Team (DMT)
2015 – 2017	AHNS CORE Study Section
2015 – 2018	ATA Development Committee
2014 – Present	Cedars-Sinai Cancer Quality Committee
2014 – Present	Cedars-Sinai Cancer Committee
2013 – 2016	AAO-HNS Head and Neck Surgery & Oncology Committee
2013 – 2016	AAO-HNS Medical Informatics Committee

**EDITORIAL BOARDS**

2018 – Present	<i>Endocrine Practice</i>
2021 – Present	<i>Annals of Thyroid</i>
2021 – Present	<i>Clinical Thyroidology</i>

**JOURNAL PEER REVIEW**

2015 – Present	<i>Thyroid</i>
2015 – Present	<i>Laryngoscope</i>
2014 – Present	<i>Cancer</i>
2014 – Present	<i>Otolaryngology-Head &amp; Neck Surgery</i>
2014 – Present	<i>Head &amp; Neck</i>

**WEB DEVELOPMENT PROJECTS**

2007 – 2011	Stanford Otolaryngology-Head & Neck Surgery Resident Portal    <a href="http://trachea.stanford.edu">http://trachea.stanford.edu</a>
2003 – 2004	Minority Health Conference    <a href="http://www.medstudent.ucla.edu/mhc/mhc03">http://www.medstudent.ucla.edu/mhc/mhc03</a>
1998 – 2000	Harvard/PBHA Chinatown Committee    <a href="http://hcs.harvard.edu/~chtn">http://hcs.harvard.edu/~chtn</a>
1998 – 2000	Christopher A. Walsh MD, PhD Laboratory    <a href="http://www.walshlab.org">http://www.walshlab.org</a>

**EMPLOYMENT**

New York, NY	<b>Investment Banking Analyst</b>
2000 – 2001	<b>J.P. Morgan &amp; Company: Industrials Division</b> <ul style="list-style-type: none"><li>• Lead junior analyst on large-cap mergers, divestitures, credit facility financings, spin-offs, and IPOs.</li><li>• Transactions: Johns Manville acquisition by Berkshire Hathaway, Tsakos Shipping IPO.</li></ul>
Chicago, IL	<b>Bond Trader Assistant</b>
Summer 1997	<b>Chicago Board of Trade: Gelber Group</b> <ul style="list-style-type: none"><li>• Processed transactions for 20-trader clearing corporation on bond and grain room floors.</li></ul>

**COURSES AND SYMPOSIA**

Los Angeles, CA	<b>Course Co-Director</b>
October 2016	Advances in the Management of Thyroid Cancer Conference. Cedars-Sinai Medical Center.
Los Angeles, CA	<b>Course Director</b>
October 2015	Southern California Head and Neck Consortium Meeting. Cedars-Sinai Medical Center.

**LICENSURE & CERTIFICATION**

2012 – Present	American Board of Otolaryngology (License No. 20792)
2006 – Present	State of California (License No. A102384)
2011 – 2014	State of New York (License No. 260338)